Biotechnology - Gilead Sciences

Filter

Current filters:

Gilead Sciences

Popular Filters

1 to 25 of 122 results

Gilead acquires Phenex program for NASH and other liver diseases

Gilead acquires Phenex program for NASH and other liver diseases

06-01-2015

US biotech major Gilead Sciences and privately-held German biotech firm Phenex Pharmaceuticals have signed…

AvogenxBiotechnologyGilead SciencesIntercept PharmaceuticalsMergers & AcquisitionsNephrology and HepatologyPhenex Pharmaceuticals

Gilead and Ono enter into a licensing agreement for ONO-4059

Gilead and Ono enter into a licensing agreement for ONO-4059

19-12-2014

Japanese pharma company Ono Pharmaceutical and US biotech major Gilead Sciences have entered into a licensing…

BiotechnologyGilead SciencesLicensingOncologyOno PharmaceuticalONO-4059Research

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

15-12-2014

US biotech major Gilead Sciences has appointed Philippe Bishop as senior vice president of hematology…

BiotechnologyBoardroomGilead SciencesHematologyOncologyUSA

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

10-12-2014

US law firm Chimicles & Tikellis of Haverford, PA, has filed a law suit on behalf of the Southeastern…

Anti-viralsBiotechnologyGilead SciencesLawLegalPricingSocial IssuesSovaldiUnited StatesUSA

Government action needed to slash prices for hepatitis C treatments, says US advocacy

Government action needed to slash prices for hepatitis C treatments, says US advocacy

04-12-2014

The US federal government should act to dramatically lower the cost of new and prohibitively pricey medications…

Anti-viralsBiotechnologyGilead SciencesPricingSovaldiUSA

Gilead Sciences’ Harvoni gains EU approval

Gilead Sciences’ Harvoni gains EU approval

19-11-2014

The European Commission yesterday granted marketing authorization for US biotech antiviral specialists…

Anti-viralsBiotechnologyEuropeGilead SciencesHarvoniRegulationSovaldi

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014

US surveyed specialists anticipate prescribing Gilead Sciences’ Harvoni to a high proportion of their…

Anti-viralsBiotechnologyGilead SciencesHarvoniJanssenMarkets & MarketingMedivirOlysioSovaldiUSA

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

29-10-2014

There was mixed news late yesterday from US anti-virals major Gilead Sciences, when the biotech posted…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldiUSA

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

23-10-2014

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniMarkets & MarketingPricingSovaldiUSA

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

12-10-2014

As was largely expected, the US Food and Drug Administration on Friday approved biotech firm Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniPricingRegulationSovaldiUSA

AfriCoLeish launches Phase III study on Gilead's AmBisome in treatment of visceral leishmaniasis

AfriCoLeish launches Phase III study on Gilead's AmBisome in treatment of visceral leishmaniasis

06-10-2014

AfriCoLeish, the international research and development consortium formed by six research organizations…

AfriCoLeishAmbisomeAnti-viralsBiotechnologyEthiopiaGilead SciencesResearch

Gilead files for Japanese approval of ledipasvir/sofosbuvir for hepatitis C

24-09-2014

Gilead Sciences has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationsofosbuvir

Gilead's TAF-based HIV regimen meets 48-week primary objective

Gilead's TAF-based HIV regimen meets 48-week primary objective

24-09-2014

Gilead Sciences says that two Phase III clinical trials (Studies 104 and 111) evaluating an investigational…

Anti-viralsBiotechnologyGilead SciencesResearchtenofovir alafenamideUSA

European Commission approves Gilead’s Zydelig for blood cancer

European Commission approves Gilead’s Zydelig for blood cancer

19-09-2014

The European Commission has granted marketing authorization for US biotech major Gilead Sciences’ Zydelig…

BiotechnologyEuropeGilead SciencesLymphomaMedicineOncologyRegulationZydelig

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

17-09-2014

US biotech major Gilead Sciences has announced disappointing results from a Phase II study evaluating…

BiotechnologyGilead SciencesOncologyResearchsimtuzumabUSA

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

Gilead gets favorable ruling in Roche arbitration

Gilead gets favorable ruling in Roche arbitration

17-08-2014

US biotech major Gilead Sciences said on Friday in a Security and Exchange Commission filing that an…

Anti-viralsArbitrationBiotechnologyBusiness FinanceBusiness FinanceGilead SciencesLegalPatentsPharmassetRocheSovaldiUSA

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

15-08-2014

In further draft guidance published today, UK drugs watchdog the National Institute for Health and Care…

Anti-viralsBiotechnologyGilead SciencesHepatitis CPricingRegulationRibavirinSovaldiUK

Vertex to drop hep C drug Incivek following poor sales

14-08-2014

Struggling US Biotech firm Vertex Pharmaceuticals has said it will cease marketing its hepatitis C treatment…

Anti-viralsBiotechnologyGilead SciencesHepatitis C treatmentIncivekJohnson & JohnsonMarkets & MarketingSovaldiTelaprevirUSAVertex Pharmaceuticals

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead

01-08-2014

US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

EMA’s CHMP backs approval of two new treatment options for rare cancers

EMA’s CHMP backs approval of two new treatment options for rare cancers

26-07-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use, at its July meeting,…

BiotechnologyEuropeFinancialGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonOncologyRegulationZydelig

1 to 25 of 122 results

Back to top